Home Recalls D-1285-2022
Class II · Moderate risk Terminated Initiated Jul 7, 2022 (4 years ago)
Aripiprazole Tablets, USP 20 mg, packaged in a) 1,000-count bottle (NDC 60505-2676-8…
Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.
Why it was recalled
Failed dissolution specifications: OOS for dissolution at the 12-month stability time point.
What was recalled
Aripiprazole Tablets, USP 20 mg, packaged in a) 1,000-count bottle (NDC 60505-2676-8, UPC 3 60505 26768 2), b) 30-count bottle (NDC 60505-2676-3, UPC 3 60505 26763 7), Rx only, Manufactured by: Apotex, Inc. Toronto, Ontario Canada M9L 1T9 Manufactured for: Apotex Corp. Weston, Florida 33326
Recalling firm Apotex Corp.
NDC code 60505-2676-8
Origin FL, United States
Initiated by Voluntary: Firm initiated
FDA recall number D-1285-2022
What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.
Class II · Moderate risk Ongoing May 27, 2026
Reason Product Mix-Up: A bottle containing Voriconazole Tablets 50 mg was labelled and distributed as Aripiprazole Tablets USP 30 mg.
Class II · Moderate risk Ongoing Aug 28, 2025
Reason Superpotent drug
Class III · Low risk Ongoing Apr 9, 2024
Reason Cross Contamination with Other Products
Class III · Low risk Ongoing Apr 9, 2024
Reason Cross Contamination with Other Products
Class III · Low risk Ongoing Apr 9, 2024
Reason Cross Contamination with Other Products